Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape

Ferris, Robert L.; Jaffee, Elizabeth M.; Ferrone, Soldano

doi:10.1200/jco.2009.27.6360

Cited by 321Monoclonal and Polyclonal Antibodies ResearchCancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape

Open access

Ferris, Robert L., Jaffee, Elizabeth M., Ferrone, Soldano·2010·Journal of Clinical Oncology

DOI 10.1200/jco.2009.27.6360PMC PMC2954137

Open this paper in CoChat — free account

Abstract

PURPOSE: Tumor antigen (TA) -targeted monoclonal antibodies (mAb), rituximab, trastuzumab, and cetuximab, are clinically effective for some advanced malignancies, especially in conjunction with chemotherapy and/or radiotherapy. However, these results are only seen in a subset (20% to 30%) of patients. We discuss the immunologic mechanism(s) underlying these clinical findings and their potential role in the variability in patients' clinical response. METHODS: We reviewed the evidence indicating that the effects of TA-targeted mAb-based immunotherapy are mediated not only by inhibition of signaling pathways, but also by cell-mediated cytotoxicity triggered by the infused TA-targeted mAb. We analyzed the immunologic variables that can influence the outcome of antibody-dependent cell-mediated cytotoxicity (ADCC) in vitro and in animal model systems. We also analyzed the correlation reported between these variables and the clinical response to mAb-based immunotherapy. RESULTS: Of the variables that influence ADCC mediated by TA-targeted mAb, only polymorphisms of Fcγ receptors (FcγR) expressed by patients' lymphocytes were correlated with clinical efficacy. However, this correlation is not absolute and is not observed in all malignancies. Thus other variables may be responsible for the antitumor effects seen in mAb-treated patients. We discuss the evidence that triggering of TA-specific cellular immunity by TA-targeted mAb, in conjunction with immune escape mechanisms used by tumor cells, may contribute to the differential clinical responses to mAb-based immunotherapy. CONCLUSION: Identification of the mechanism(s) underlying the clinical response of patients with cancer treated with TA-targeted mAb is crucial to optimizing their application in the clinic and to selecting the patients most likely to benefit from their use.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1200/jco.2009.27.6360

Cites

122 of 122 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The therapeutic efficacy of multiple mAbs targeting plasma membrane receptors in oncogenesis stems at least partly from bridging malignant cells and FcγR-expressing immune effector cells, leading to ADCC.
“The therapeutic efficacy of multiple mAbs targeting plasma membrane receptors involved in oncogenesis stems (at least in part) from their ability to bridge malignant cells and immune effector cells expressing Fc gamma receptors (Fc g Rs), culminating in antibody-dependent cellular cytotoxicity (ADCC) (Ferris et al., 2010).”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Ferris et al., 2010

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck
Bonner, J. A., Harari, P. M., Giralt, J., Azarnia, N., Shin, D. M., Cohen, R. B., Jones, C. U., Sur, R. K., Raben, D., Jassem, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053422 · Cited by 5,109 · see citing works
Immunotherapy of Diffuse Gliomas: Biological Background, Current Status and Future Developments
Grauer, O. M., Wesseling, P., & Adema, G. J. (2009) · Brain Pathology · doi:10.1111/j.1750-3639.2009.00315.x · Cited by 4,023 · see citing works
Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
Vermorken, J. B., Mesia, R., Rivera, F., Remenar, E., Kawecki, A., Rottey, S., Erfan, J., Zabolotnyy, D., Kienzer, H.-R., Cupissol, D., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802656 · Cited by 3,726 · see citing works
Postoperative Concurrent Radiotherapy and Chemotherapy for High-Risk Squamous-Cell Carcinoma of the Head and Neck
Cooper, J. S., Pajak, T. F., Forastiere, A. A., Jacobs, J., Campbell, B. H., Saxman, S. B., Kish, J. A., Kim, H. E., Cmelak, A. J., Rotman, M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032646 · Cited by 3,271 · see citing works
IgG Fc Receptors
Ravetch, J. V., & Bolland, S. M. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.275 · Cited by 1,653 · see citing works
Cd8+ but Not Cd8− Dendritic Cells Cross-Prime Cytotoxic T Cells in Vivo
den Haan, J. M. M., Lehar, S. M., & Bevan, M. J. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.12.1685 · Cited by 1,319 · see citing works
Two Immunoglobulin G Fragment C Receptor Polymorphisms Independently Predict Response to Rituximab in Patients With Follicular Lymphoma
Weng, W., & Levy, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.013 · Cited by 1,300 · see citing works
Monoclonal antibody therapy of cancer
Adams, G. P., & Weiner, L. M. (2005) · Nature Biotechnology · doi:10.1038/nbt1137 · Cited by 1,245 · see citing works
Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity
Yun, C.-H., Boggon, T. J., Li, Y., Woo, M. S., Greulich, H., Meyerson, M., & Eck, M. J. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.12.017 · Cited by 1,192 · see citing works
Levels of TGF-α and EGFR Protein in Head and Neck Squamous Cell Carcinoma and Patient Survival
Grandis, J. R., Melhem, M. F., Gooding, W. E., Day, R., Holst, V. A., Wagener, M. M., Drenning, S. D., & Tweardy, D. J. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.11.824 · Cited by 1,112 · see citing works
Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.
Chung, K. Y., Shia, J., Kemeny, N. E., Shah, M., Schwartz, G. K., Tse, A., Hamilton, A., Pan, D., Schrag, D., Schwartz, L., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.037 · Cited by 1,081 · see citing works
Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/ <i>neu</i> –Positive Metastatic Breast Cancer
Musolino, A., Naldi, N., Bortesi, B., Pezzuolo, D., Capelletti, M., Missale, G., Laccabue, D., Zerbini, A., Camisa, R., Bisagni, G., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8957 · Cited by 981 · see citing works
Gain of function mutations in p53
Dittmer, D., Pati, S., Zambetti, G., Chu, S., Teresky, A. K., Moore, M., Finlay, C., & Levine, A. J. (1993) · Nature Genetics · doi:10.1038/ng0593-42 · Cited by 894 · see citing works
Dendritic Cells Prime Natural Killer Cells by trans-Presenting Interleukin 15
Lucas, M., Schachterle, W., Oberle, K., Aichele, P., & Diefenbach, A. (2007) · Immunity · doi:10.1016/j.immuni.2007.03.006 · Cited by 888 · see citing works
Phase III Randomized Trial of Cisplatin Plus Placebo Compared With Cisplatin Plus Cetuximab in Metastatic/Recurrent Head and Neck Cancer: An Eastern Cooperative Oncology Group Study
Burtness, B. A., Goldwasser, M. A., Flood, W. A., Mattar, B. I., & Forastiere, A. A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.4646 · Cited by 878 · see citing works
Tumor antigen-specific T helper cells in cancer immunity and immunotherapy
Knutson, K. L., & Disis, M. L. (2005) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-004-0653-2 · Cited by 689 · see citing works
Increased Epidermal Growth Factor Receptor Gene Copy Number Is Associated With Poor Prognosis in Head and Neck Squamous Cell Carcinomas
Chung, C. H., Ely, K., McGavran, L., Varella‐Garcia, M., Parker, J. S., Parker, N. B., Jarrett, C., Carter, J., Murphy, B. A., Netterville, J. L., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.2587 · Cited by 570 · see citing works
Impact of FcγRIIa-FcγRIIIa Polymorphisms and <i>KRAS</i> Mutations on the Clinical Outcome of Patients With Metastatic Colorectal Cancer Treated With Cetuximab Plus Irinotecan
Bibeau, F., Lopez-Crapez, E., Di Fiore, F., Thezenas, S., Ychou, M., Blanchard, F., Lamy, A., Penault-Llorca, F., Frébourg, T., Michel, P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0463 · Cited by 521 · see citing works
FCGR2A and FCGR3A Polymorphisms Associated With Clinical Outcome of Epidermal Growth Factor Receptor–Expressing Metastatic Colorectal Cancer Patients Treated With Single-Agent Cetuximab
Zhang, W., Gordon, M. A., Schultheis, A. M., Yang, D., Nagashima, F., Azuma, M., Chang, H.-M., Borucka, E., Lurje, G., Sherrod, A. E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.8021 · Cited by 482 · see citing works
Antibody-Dependent Cellular Cytotoxicity Mediated by Cetuximab against Lung Cancer Cell Lines
Kurai, J., Chikumi, H., Hashimoto, K., Yamaguchi, K., Yamasaki, A., Sako, T., Touge, H., Makino, H., Takata, M., Miyata, M., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1726 · Cited by 435 · see citing works
Rituximab-Dependent Cytotoxicity by Natural Killer Cells
Dall’Ozzo, S., Tartas, S., Paintaud, G., Cartron, G., Colombat, P., Bardos, P., Watier, H., & Thibault, G. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2862 · Cited by 434 · see citing works
Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts
Cragg, M. S., Morgan, S. M., Chan, H. T. C., Morgan, B. P., Filatov, A. V., Johnson, P., French, R. R., & Glennie, M. J. (2003) · Blood · doi:10.1182/blood-2002-06-1761 · Cited by 390 · see citing works
Inducing Tumor Immunity through the Selective Engagement of Activating Fcγ Receptors on Dendritic Cells
Kalergis, A. M., & Ravetch, J. V. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020338 · Cited by 370 · see citing works
Dendritic Cells Mediate NK Cell Help for Th1 and CTL Responses: Two-Signal Requirement for the Induction of NK Cell Helper Function
Mailliard, R. B., Son, Y., Redlinger, R. E., Coates, P. T. H., Giermasz, A. S., Morel, P. A., Storkus, W. J., & Kaliński, P. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.5.2366 · Cited by 353 · see citing works
Antitumor Monoclonal Antibodies Enhance Cross-Presentation of Cellular Antigens and the Generation of Myeloma-specific Killer T Cells by Dendritic Cells
Dhodapkar, K. M., Krasovsky, J., Williamson, B., & Dhodapkar, M. V. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20011097 · Cited by 348 · see citing works
Addition of Rituximab to Standard Chemotherapy Improves the Survival of Both the Germinal Center B-Cell–Like and Non–Germinal Center B-Cell–Like Subtypes of Diffuse Large B-Cell Lymphoma
Fu, K., Weisenburger, D. D., Choi, W. W. L., Perry, K., Smith, L. M., Shi, X., Hans, C. P., Greiner, T. C., Bierman, P. J., Bociek, R. G., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.9277 · Cited by 334 · see citing works
Complement activation plays a key role in the side‐effects of rituximab treatment
van der Kolk, L. E., Grillo-López, A. J., Baars, J. W., Hack, C. E., & van Oers, M. H. J. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.03166.x · Cited by 327 · see citing works
Monoclonal antibodies for cancer immunotherapy
Weiner, L. M., Dhodapkar, M. V., & Ferrone, S. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60251-8 · Cited by 305 · see citing works
Self-citation
Concurrent Trastuzumab and HER2/neu-Specific Vaccination in Patients With Metastatic Breast Cancer
Disis, M. L., Wallace, D. R., Gooley, T. A., Dang, Y., Slota, M., Lu, H., Coveler, A. L., Childs, J. S., Higgins, D. M., Fintak, P. A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.6789 · Cited by 301 · see citing works
The Mannose Receptor Mediates Uptake of Soluble but Not of Cell-Associated Antigen for Cross-Presentation
Burgdorf, S., Lukacs‐Kornek, V., & Kurts, C. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.11.6770 · Cited by 295 · see citing works
IL-18–induced CD83+CCR7+NK helper cells
Mailliard, R. B., Alber, S. M., Shen, H., Watkins, S. C., Kirkwood, J. M., Herberman, R. B., & Kaliński, P. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050128 · Cited by 285 · see citing works
Immune complex–mediated antigen presentation induces tumor immunity
Rafiq, K., Bergtold, A., & Clynes, R. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15640 · Cited by 266 · see citing works
Binding of Submaximal C1q Promotes Complement-Dependent Cytotoxicity (CDC) of B Cells Opsonized with Anti-CD20 mAbs Ofatumumab (OFA) or Rituximab (RTX): Considerably Higher Levels of CDC Are Induced by OFA than by RTX
Pawluczkowycz, A. W., Beurskens, F. J. M., Beum, P. V., Lindorfer, M. A., van de Winkel, J. G. J., Parren, P. W. H. I., & Taylor, R. P. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900632 · Cited by 262 · see citing works
Anti-CD20 monoclonal antibodies: historical and future perspectives
Lim, S. H., Beers, S. A., French, R. R., Johnson, P., Glennie, M. J., & Cragg, M. S. (2009) · Haematologica · doi:10.3324/haematol.2008.001628 · Cited by 246 · see citing works
Elements Related to Heterogeneity of Antibody-Dependent Cell Cytotoxicity in Patients Under Trastuzumab Therapy for Primary Operable Breast Cancer Overexpressing Her2
Varchetta, S., Gibelli, N., Oliviero, B., Nardini, E., Gennari, R., Gatti, G. M., Silva, L. S., Villani, L., Tagliabue, E., Ménard, S., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2068 · Cited by 239 · see citing works
Timed Sequential Treatment With Cyclophosphamide, Doxorubicin, and an Allogeneic Granulocyte-Macrophage Colony-Stimulating Factor–Secreting Breast Tumor Vaccine: A Chemotherapy Dose-Ranging Factorial Study of Safety and Immune Activation
Emens, L. A., Asquith, J. M., Leatherman, J. M., Kobrin, B. J., Petrik, S., Laiko, M., Levi, J. A., Daphtary, M. M., Biedrzycki, B. A., Wolff, A. C., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.3494 · Cited by 236 · see citing works
Self-citation
HGF and c-Met Participate in Paracrine Tumorigenic Pathways in Head and Neck Squamous Cell Cancer
Knowles, L. M., Stabile, L. P., Egloff, A. M., Rothstein, M. E., Thomas, S. M., Gubish, C. T., Lerner, E. C., Seethala, R. R., Suzuki, S., Quesnelle, K. M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-3252 · Cited by 232 · see citing works
Self-citation
Immune complex–mediated antigen presentation induces tumor immunity
Rafiq, K., Bergtold, A., & Clynes, R. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215640 · Cited by 232 · see citing works
Immune Escape Associated with Functional Defects in Antigen-Processing Machinery in Head and Neck Cancer
Ferris, R. L., Whiteside, T. L., & Ferrone, S. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2750 · Cited by 224 · see citing works
Self-citation
Human IgG2 Antibodies against Epidermal Growth Factor Receptor Effectively Trigger Antibody-Dependent Cellular Cytotoxicity but, in Contrast to IgG1, Only by Cells of Myeloid Lineage
Schneider‐Merck, T., van Bueren, J. J. L., Berger, S., Rossen, K., van Berkel, P. H. C., Derer, S., Beyer, T. D., Lohse, S., Bleeker, W. K., Peipp, M., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900847 · Cited by 223 · see citing works
MECT1-MAML2 Fusion Transcript Defines a Favorable Subset of Mucoepidermoid Carcinoma
Okabe, M., Miyabe, S., Nagatsuka, H., Terada, A., Hanai, N., Yokoi, M., Shimozato, K., Eimoto, T., Nakamura, S., Nagai, N., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2376 · Cited by 221 · see citing works
Biology of Interactions: Antiepidermal Growth Factor Receptor Agents
Harari, P. M., Allen, G. W., & Bonner, J. A. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.8984 · Cited by 214 · see citing works
Augmented HER-2–Specific Immunity during Treatment with Trastuzumab and Chemotherapy
Taylor, C., Hershman, D. L., Shah, N. D., Suciu‐Foca, N., Petrylak, D. P., Taub, R. N., Vahdat, L. T., Cheng, B., Pegram, M. D., Knutson, K. L., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0507 · Cited by 212 · see citing works
‘Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions’
Bonavida, B. (2007) · Oncogene · doi:10.1038/sj.onc.1210365 · Cited by 210 · see citing works
Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species
Bellosillo, B., Villamor, N., López‐Guillermo, A., Marcé, S., Esteve, J., Campo, E., Colomer, D., & Montserrat, E. (2001) · Blood · doi:10.1182/blood.v98.9.2771 · Cited by 205 · see citing works
Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response
Abès, R., Gélizé, E., Fridman, W. H., & Teillaud, J. (2010) · Blood · doi:10.1182/blood-2009-10-248609 · Cited by 196 · see citing works
Clinical Outcome of Lymphoma Patients After Idiotype Vaccination Is Correlated With Humoral Immune Response and Immunoglobulin G Fc Receptor Genotype
Weng, W., Czerwinski, D. K., Timmerman, J. M., Hsu, F. J., & Levy, R. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.003 · Cited by 191 · see citing works
Signaling Through NK Cell-Associated CD137 Promotes Both Helper Function for CD8+ Cytolytic T Cells and Responsiveness to IL-2 But Not Cytolytic Activity
Wilcox, R. A., Tamada, K., Strome, S. E., & Chen, L. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.8.4230 · Cited by 181 · see citing works
Phase I/II Study of Cetuximab in Combination With Cisplatin or Carboplatin and Fluorouracil in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Bourhis, J., Rivera, F., Mesı́a, R., Awada, A. H., Geoffrois, L., Borel, C., Humblet, Y., Pousa, A. L., Hitt, R., Villegas, M. E. V., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.3547 · Cited by 174 · see citing works
Molecular predictors of response to trastuzumab and lapatinib in breast cancer
Esteva, F. J., Yu, D., Hung, M., & Hortobágyi, G. N. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.216 · Cited by 168 · see citing works
Complement-Dependent Tumor Cell Lysis Triggered by Combinations of Epidermal Growth Factor Receptor Antibodies
Dechant, M., Weisner, W., Berger, S., Peipp, M., Beyer, T. D., Schneider‐Merck, T., van Bueren, J. J. L., Bleeker, W. K., Parren, P. W. H. I., van de Winkel, J. G. J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6226 · Cited by 165 · see citing works
Natural Killer Cells Produce T Cell–Recruiting Chemokines in Response to Antibody-Coated Tumor Cells
Roda, J. M., Parihar, R., MAGRO, C. M. J., Nuovo, G. J., Tridandapani, S., & Carson, W. E. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2429 · Cited by 165 · see citing works
Therapies Directed Against Epidermal Growth Factor Receptor in Aerodigestive Carcinomas
Karamouzis, M. V., Grandis, J. R., & Argiris, A. E. (2007) · JAMA · doi:10.1001/jama.298.1.70 · Cited by 163 · see citing works
Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells
López‐Albaitero, A., Lee, S. C., Morgan, S., Grandis, J. R., Gooding, W. E., Ferrone, S., & Ferris, R. L. (2009) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-009-0697-4 · Cited by 160 · see citing works
Self-citation
Insulin-Like Growth Factor-1 Receptor Inhibition Induces a Resistance Mechanism via the Epidermal Growth Factor Receptor/HER3/AKT Signaling Pathway: Rational Basis for Cotargeting Insulin-Like Growth Factor-1 Receptor and Epidermal Growth Factor Receptor in Hepatocellular Carcinoma
Desbois‐Mouthon, C., Baron, A., Eggelpoël, M.-J. B.-V., Fartoux, L., Venot, C., Bladt, F., Housset, C., & Rosmorduc, O. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2980 · Cited by 157 · see citing works
Role of Antigen-Processing Machinery in the In Vitro Resistance of Squamous Cell Carcinoma of the Head and Neck Cells to Recognition by CTL
López‐Albaitero, A., Nayak, J. V., Ogino, T., Machandia, A., Gooding, W. E., DeLeo, A. B., Ferrone, S., & Ferris, R. L. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.6.3402 · Cited by 156 · see citing works
Self-citation
The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors.
Reilly, R. T., Machiels, J.-P., Emens, L. A., Ercolini, A. M., Okoye, F. I., Lei, R. Y., Weintraub, D., & Jaffee, E. M. (2001) · PubMed · Cited by 151 · see citing works
Self-citation
Cross-talk between G Protein–Coupled Receptor and Epidermal Growth Factor Receptor Signaling Pathways Contributes to Growth and Invasion of Head and Neck Squamous Cell Carcinoma
Thomas, S. M., Bhola, N. E., Zhang, Q. H., Contrucci, S., Wentzel, A. L., Freilino, M. L., Gooding, W. E., Siegfried, J. M., Chan, D. C. F., & Grandis, J. R. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-2876 · Cited by 151 · see citing works
The Activation of Natural Killer Cell Effector Functions by Cetuximab-Coated, Epidermal Growth Factor Receptor–Positive Tumor Cells is Enhanced By Cytokines
Roda, J. M., Joshi, T., Butchar, J. P., McAlees, J. W., Lehman, A., Tridandapani, S., & Carson, W. E. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0865 · Cited by 146 · see citing works
Mechanisms of resistance to HER family targeting antibodies
Kruser, T. J., & Wheeler, D. L. (2010) · Experimental Cell Research · doi:10.1016/j.yexcr.2010.01.009 · Cited by 141 · see citing works
Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neck
Sharafinski, M. E., Ferris, R. L., Ferrone, S., & Grandis, J. R. (2010) · Head & Neck · doi:10.1002/hed.21365 · Cited by 127 · see citing works
Self-citation
Complement Activation on B Lymphocytes Opsonized with Rituximab or Ofatumumab Produces Substantial Changes in Membrane Structure Preceding Cell Lysis
Beum, P. V., Lindorfer, M. A., Beurskens, F. J. M., Stukenberg, P. T., Lokhorst, H. M., Pawluczkowycz, A. W., Parren, P. W. H. I., van de Winkel, J. G. J., & Taylor, R. P. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.1.822 · Cited by 126 · see citing works
Fc receptor signaling and trafficking: a connection for antigen processing
Amigorena, S., & Bonnerot, C. (1999) · Immunological Reviews · doi:10.1111/j.1600-065x.1999.tb01372.x · Cited by 123 · see citing works
Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2/neu carcinomas
Curcio, C., Carlo, E. D., Clynes, R., Smyth, M. J., Boggio, K., Quaglino, E., Spadaro, M., Colombo, M. P., Amici, A. R. D., Lollini, P., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200317426 · Cited by 122 · see citing works
Natural killer–dendritic cell cross-talk in cancer immunotherapy
Kaliński, P., Mailliard, R. B., Giermasz, A. S., Zeh, H. J., Basse, P. H., Bartlett, D. L., Kirkwood, J. M., Lotze, M. T., & Herberman, R. B. (2005) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.5.10.1303 · Cited by 117 · see citing works
Fc-dependent expression of CD137 on human NK cells: insights into “agonistic” effects of anti-CD137 monoclonal antibodies
Lin, W., Voskens, C., Zhang, X., Schindler, D. G., Wood, A., Burch, E. E., Wei, Y., Chen, L., Tian, G., Tamada, K., et al. (2008) · Blood · doi:10.1182/blood-2007-11-122465 · Cited by 116 · see citing works
Human Leukocyte Antigen (HLA) Class I Defects in Head and Neck Cancer: Molecular Mechanisms and Clinical Significance
Ferris, R. L., Hunt, J. L., & Ferrone, S. (2005) · Immunologic Research · doi:10.1385/ir:33:2:113 · Cited by 115 · see citing works
Self-citation
Microglia induce myelin basic protein-specific T cell anergy or T cell activation, according to their state of activation
Matyszak, M. K., Denis‐Donini, S., Citterio, S., Longhi, R., Granucci, F., & Ricciardi‐Castagnoli, P. (1999) · European Journal of Immunology · doi:10.1002/(sici)1521-4141(199910)29:10 · Cited by 114 · see citing works
Antibody-enhanced cross-presentation of self antigen breaks T cell tolerance
Harbers, S. O., Crocker, A., Catalano, G., D’Agati, V. D., Jung, S., Desai, D. D., & Clynes, R. (2007) · Journal of Clinical Investigation · doi:10.1172/jci29470 · Cited by 105 · see citing works
HLA-G expression in human ovarian carcinoma counteracts NK cell function
Lin, A., Yan, W., Xu, H., Gan, M. F., Cai, J., Zhu, M., & Zhou, M. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm356 · Cited by 101 · see citing works
Binding of Rituximab, Trastuzumab, Cetuximab, or mAb T101 to Cancer Cells Promotes Trogocytosis Mediated by THP-1 Cells and Monocytes
Beum, P. V., Mack, D. A., Pawluczkowycz, A. W., Lindorfer, M. A., & Taylor, R. P. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.11.8120 · Cited by 94 · see citing works
Immunoglobulin G Fc Receptor FcγRIIIa 158 V/F Polymorphism Correlates With Rituximab-Induced Neutropenia After Autologous Transplantation in Patients With Non-Hodgkin's Lymphoma
Weng, W., Negrin, R. S., Lavori, P. W., & Horning, S. J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.0274 · Cited by 93 · see citing works
Phagocytosis requires repeated triggering of macrophage phagocytic receptors during particle ingestion
Shaw, D. R., & Griffin, F. M. (1981) · Nature · doi:10.1038/289409a0 · Cited by 92 · see citing works
Immune Activation by Epidermal Growth Factor Receptor–Specific Monoclonal Antibody Therapy for Head and Neck Cancer
López‐Albaitero, A., & Ferris, R. L. (2007) · Archives of Otolaryngology - Head and Neck Surgery · doi:10.1001/archotol.133.12.1277 · Cited by 92 · see citing works
Self-citation
Antigen-Processing Machinery in Human Dendritic Cells: Up-Regulation by Maturation and Down-Regulation by Tumor Cells
Whiteside, T. L., Stanson, J., Shurin, M. R., & Ferrone, S. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.3.1526 · Cited by 90 · see citing works
Self-citation
Ten years of rituximab in NHL
Winter, M. C., & Hancock, B. W. (2009) · Expert Opinion on Drug Safety · doi:10.1517/14740330902750114 · Cited by 89 · see citing works
A Comparison of thein Vitroandin VivoActivities of IgG and F(ab′)2 Fragments of a Mixture of Three Monoclonal Anti-Her-2 Antibodies
Spiridon, C., Guinn, S. E., & Vitetta, E. S. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0549 · Cited by 88 · see citing works
Optimal timing for adjuvant radiation therapy in breast cancer
Tsoutsou, P. P., Koukourakis, M. I., Azria, D., & Belkacémi, Y. (2008) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2008.09.002 · Cited by 87 · see citing works
Antitumor mechanisms of combined gastrin-releasing peptide receptor and epidermal growth factor receptor targeting in head and neck cancer
Zhang, Q. H., Bhola, N. E., Lui, V. W. Y., Siwak, D. R., Thomas, S. M., Gubish, C. T., Siegfried, J. M., Mills, G. B., Shin, D. M., & Grandis, J. R. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0678 · Cited by 86 · see citing works
The upgraded role of HER3 and HER4 receptors in breast cancer
Koutras, A. K., Fountzilas, G., Kalogeras, K. T., Starakis, I., Iconomou, G., & Kalofonos, H. P. (2009) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2009.04.011 · Cited by 86 · see citing works
Regulatory T cells and tumor immunity
Chattopadhyay, S., Chakraborty, N. G., & Mukherji, B. (2005) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-005-0699-9 · Cited by 83 · see citing works
Phase I Active Immunotherapy With Combination of Two Chimeric, Human Epidermal Growth Factor Receptor 2, B-Cell Epitopes Fused to a Promiscuous T-Cell Epitope in Patients With Metastatic and/or Recurrent Solid Tumors
Kaumaya, P. T. P., Foy, K. C., Garrett, J. T., Rawale, S. V., Vicari, D., Thurmond, J. M., Lamb, T., Mani, A., Kane, Y., Balint, C. R., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.3883 · Cited by 83 · see citing works
Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer
Mariani, G., Fasolo, A., Benedictis, E. D., & Gianni, L. (2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1298 · Cited by 80 · see citing works
Radiation Combined With EGFR Signal Inhibitors: Head and Neck Cancer Focus
Harari, P. M., & Huang, S.-F. K. (2005) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2005.08.005 · Cited by 80 · see citing works
Antibody association with HER-2/neu–targeted vaccine enhances CD8+ T cell responses in mice through Fc-mediated activation of DCs
Kim, P. S., Armstrong, T. D., Hong, S., Wolpoe, M. E., Weiss, V. L., Manning, E. A., Huang, L., Murata, S., Sgouros, G., Emens, L. A., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34333 · Cited by 78 · see citing works
Self-citation
HLA‐G protein expression as a potential immune escape mechanism in classical Hodgkin’s lymphoma
Diepstra, A., Poppema, S., Boot, M., Visser, L., Nolte, I. M., Niens, M., Meerman, G. J. T., & van den Berg, A. (2008) · Tissue Antigens · doi:10.1111/j.1399-0039.2008.01005.x · Cited by 77 · see citing works
Effector CD8+CD45RO−CD27−T cells have signalling defects in patients with squamous cell carcinoma of the head and neck
Kuss, I., Donnenberg, A. D., Gooding, W. E., & Whiteside, T. L. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6600694 · Cited by 73 · see citing works
Neutralization of complement regulatory proteins CD55 and CD59 augments therapeutic effect of herceptin against lung carcinoma cells
Chen (2009) · Oncology Reports · doi:10.3892/or_00000368 · Cited by 69 · see citing works
The GD2-specific 14G2a monoclonal antibody induces apoptosis and enhances cytotoxicity of chemotherapeutic drugs in IMR-32 human neuroblastoma cells
Kowalczyk, A., Gil, M., Horwacik, I., Odrowaz, Z., Kozbor, D., & Rokita, H. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.02.040 · Cited by 66 · see citing works
Cetuximab-mediated cellular cytotoxicity is inhibited by HLA-E membrane expression in colon cancer cells
Levy, E. M., Sycz, G., Arriaga, J. M., Barrio, M. M., von Euw, E. M., Morales, S. B., Gonzalez, M. S., Mordoh, J., & Bianchini, M. (2009) · Innate Immunity · doi:10.1177/1753425908101404 · Cited by 66 · see citing works
Current perspective – Trastuzumab
Hall, P. S., & Cameron, D. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.013 · Cited by 58 · see citing works
Gastrin-releasing peptide activates Akt through the epidermal growth factor receptor pathway and abrogates the effect of gefitinib
Liu, X., Carlisle, D. L., Swick, M. C., Gaither‐Davis, A., Grandis, J. R., & Siegfried, J. M. (2007) · Experimental Cell Research · doi:10.1016/j.yexcr.2007.01.016 · Cited by 56 · see citing works
Emerging perspectives in epidermal growth factor receptor targeting in head and neck cancer
Kim, S., Grandis, J. R., Rinaldo, A., Takes, R. P., & Ferlito, A. (2008) · Head & Neck · doi:10.1002/hed.20859 · Cited by 56 · see citing works
Recombinant humanised anti-HER2/neu antibody (Herceptin®) induces cellular death of glioblastomas
Mineo, J. ‐., Bordron, A., Quintin‐Roué, I., Loisel, S., Ster, K. L., Buhé, V., Lagarde, N., & Berthou, C. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602089 · Cited by 55 · see citing works
Antitumor Antibodies in the Treatment of Cancer: Fc Receptors Link Opsonic Antibody with Cellular Immunity
Clynes, R. (2006) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2006.02.010 · Cited by 53 · see citing works
Interaction of a human FcγRIIb1 (CD32) isoform with murine and human IgG subclasses
Warmerdam, P. A. M., van den Herik–Oudijk, I. E., Parren, P. W. H. I., WESTERDAAL, N. A. C., & Capel, P. J. (1993) · International Immunology · doi:10.1093/intimm/5.3.239 · Cited by 52 · see citing works
Maturation Pathways of Dendritic Cells Determine TAP1 and TAP2 Levels and Cross-presenting Function
López‐Albaitero, A., Mailliard, R. B., Hackman, T., Filho, P. A. A., Wang, X., Gooding, W. E., Ferrone, S., Kaliński, P., & Ferris, R. L. (2009) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181a1c24e · Cited by 49 · see citing works
Self-citation
Cetuximab-Related Tumor Lysis Syndrome in Metastatic Colon Carcinoma
Krishnan, G., D’Silva, K. J., & Al-Janadi, A. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7603 · Cited by 45 · see citing works
Antitumor effects of cytolytic T lymphocytes (CTL) and natural killer (NK) cells in head and neck cancer.
Whiteside, T. L., Chikamatsu, K., Nagashima, S., & Okada, K. (1996) · PubMed · Cited by 43 · see citing works
A Phase I Vaccine Safety and Chemotherapy Dose-Finding Trial of an Allogeneic GM-CSF–Secreting Breast Cancer Vaccine Given in a Specifically Timed Sequence with Immunomodulatory Doses of Cyclophosphamide and Doxorubicin. The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland
Emens, L. A., Armstrong, D. K., Biedrzycki, B. A., Davidson, N. E., Davis-Sproul, J. M., Fetting, J. H., Jaffee, E. M., Onners, B., Piantadosi, S., Reilly, R. T., et al. (2004) · Human Gene Therapy · doi:10.1089/104303404322886165 · Cited by 37 · see citing works
Self-citation
ROLE OF POLYMORPHIC Fc RECEPTOR Fc??RIIa IN CYTOKINE RELEASE AND ADVERSE EFFECTS OF MURINE IgG1 ANTI-CD3/T CELL RECEPTOR ANTIBODY (WT31)1
Tax, W. J. M., Tamboer, W. P. M., Jacobs, C. W. M., Frenken, L. A. M., & Koene, R. A. P. (1997) · Transplantation · doi:10.1097/00007890-199701150-00020 · Cited by 32 · see citing works
Enhanced T-Cell Responses to Glioma Cells Coated With the Anti-EGF Receptor Antibody and Targeted to Activating FcγRs on Human Dendritic Cells
Banerjee, D., Matthews, P., Matayeva, E., Kaufman, J. L., Steinman, R. M., & Dhodapkar, K. M. (2008) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31815a5892 · Cited by 31 · see citing works
Expression of the ULBP ligands for NKG2D by B‐NHL cells plays an important role in determining their susceptibility to rituximab‐induced ADCC
Inagaki, A., Ishida, T., Yano, H., Ishii, T., Kusumoto, S., Ito, A., Ri, M., Mori, F., Ding, J., Komatsu, H., et al. (2009) · International Journal of Cancer · doi:10.1002/ijc.24351 · Cited by 30 · see citing works
Novel Immunogenic HLA-A*0201-restricted Epidermal Growth Factor Receptor-specific T-cell Epitope in Head and Neck Cancer Patients
Filho, P. A. A., López‐Albaitero, A., Gooding, W. E., & Ferris, R. L. (2009) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181b8f421 · Cited by 30 · see citing works
Self-citation
Improving disease control in advanced colorectal cancer: Panitumumab and cetuximab
Rodríguez, J., Viúdez, A., Ponz‐Sarvisé, M., Gil-Aldea, I., Chopitea, A., García‐Foncillas, J., & Bazo, I. G. (2009) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2009.07.005 · Cited by 30 · see citing works
Targeting growth factor receptors: integration of novel therapeutics in the management of head and neck cancer
Lango, M. N., Shin, D. M., & Grandis, J. R. (2001) · Current Opinion in Oncology · doi:10.1097/00001622-200105000-00007 · Cited by 29 · see citing works
EGFR-targeted therapy in colorectal cancer: does immunohistochemistry deserve a role in predicting the response to cetuximab?
Valentini, A. M., Pirrelli, M., & Caruso, M. L. (2008) · PubMed · Cited by 27 · see citing works
HLA-G in Melanoma: A New Strategy to Escape from Immunosurveillance?
Ugurel, S., Reinhold, U., & Tilgen, W. (2002) · Oncology Research and Treatment · doi:10.1159/000055222 · Cited by 26 · see citing works
Interleukin 2 gene transfer prevents NKG2D suppression and enhances antitumor efficacy in combination with cisplatin for head and neck squamous cell cancer.
Li, D., Ronson, B. B., Guo, M., Liu, S., Bishop, J. S., Echo, D. A. V., & O'Malley, B. W. (2002) · PubMed · Cited by 24 · see citing works
Association of FcγRIIa and FcγRIIa polymorphisms with clinical outcome in metastatic colorectal cancer patients (mCRC) treated with cetuximab and irinotecan
Bibeau, F., Crapez, E., Fiore, F. D., Thézenas, S., Sabourin, J., Lamy, A., Frébourg, T., Michel, P., Ychou, M., & Boissière‐Michot, F. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.11004 · Cited by 23 · see citing works
Cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil (5-FU) in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R&M SCCHN) (EXTREME)
Vermorken, J. B., Mesı́a, R., Vega-Villegas, M. E., Remenár, É., Hitt, R., Kawecki, A., Rottey, S., Zabolotnyy, D., Erfan, J., & Amellal, N. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.5537 · Cited by 21 · see citing works
Immunotherapy of head and neck cancer using tumor antigen-specific monoclonal antibodies
Lee, S. C., López‐Albaitero, A., & Ferris, R. L. (2009) · Current Oncology Reports · doi:10.1007/s11912-009-0023-5 · Cited by 21 · see citing works
Self-citation
Pathologic Complete Response to Preoperative Sequential Doxorubicin/Cyclophosphamide and Single-Agent Taxane With or Without Trastuzumab in Stage II/III HER2-Positive Breast Cancer
Chumsri, S., Jeter, S. C., Jacobs, L. K., Nassar, H., Armstrong, D. K., Emens, L. A., Fetting, J. H., Lange, J. R., Riley, C. D., Tsangaris, T. N., et al. (2010) · Clinical Breast Cancer · doi:10.3816/cbc.2010.n.005 · Cited by 17 · see citing works
Differential survival following trastuzumab treatment based on quantitative HER2 expression and HER2 homodimers in a clinic-based cohort of patients with metastatic breast cancer
Toi, M., Sperinde, J., Huang, W., Saji, S., Winslow, J. W., Jin, X., Tan, Y., Ohno, S., Nakamura, S., Iwata, H., et al. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-56 · Cited by 17 · see citing works
Head and neck cancer immunotherapy: Clinical evaluation
Leibowitz, M. S., Nayak, J. V., & Ferris, R. L. (2008) · Current Oncology Reports · doi:10.1007/s11912-008-0025-8 · Cited by 15 · see citing works
Self-citation
Common adjuvant breast cancer therapies do not inhibit cancer vaccine induced T cell immunity
Coveler, A. L., Vivian Goodell, A., Webster, D. J., Salazar, L. G., Fintak, P. A., Childs, J. S., Higgins, D. M., & Disis, M. L. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-9910-y · Cited by 14 · see citing works
Expansion of natural killer cells in patients with head and neck cancer: Detection of “noninhibitory” (activating) killer Ig‐like receptors on circulating natural killer cells
Melioli, G., Semino, C., Margarino, G., Mereu, P., Scala, M., Cangemi, G., Crocetti, E., Machì, A. M., & Ferlazzo, G. (2002) · Head & Neck · doi:10.1002/hed.10198 · Cited by 14 · see citing works
Cetuximab therapy for patients with advanced squamous cell carcinomas of the head and neck
William, W. N., Kim, E. S., & Herbst, R. S. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/ncponc1321 · Cited by 13 · see citing works
Cetuximab for Metastatic Colorectal Cancer
Roila, F., Garassino, M. C., & Ballatori, E. (2009) · New England Journal of Medicine · doi:10.1056/nejmc090927 · Cited by 11 · see citing works
Cetuximab, chemotherapy and KRAS status in mCRC
Gill, S., & Goldberg, R. M. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.83 · Cited by 8 · see citing works
Cetuximab plus chemotherapy in patients with advanced NSCLC
Rasul, K. I., & Kerr, R. S. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.108 · Cited by 5 · see citing works
Untitled work
Bischof, A. (2000) · doi:10.1002/1521-4141(200003)30:3

Flagged first, then by citations

Sorted by citations

Antibody therapy of cancer
Scott, A. M., Wolchok, J. D., & Old, L. J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3236 · Cited by 2,167 · see citing works
NK cells for cancer immunotherapy
Shimasaki, N., Jain, A., & Campana, D. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0052-1 · Cited by 1,233 · see citing works
HER2-targeted therapies — a role beyond breast cancer
Oh, D.-Y., & Bang, Y.-J. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0268-3 · Cited by 1,081 · see citing works
Natural killer cells in cancer biology and therapy
Wu, S.-Y., Fu, T., Jiang, Y.-Z., & Shao, Z.-M. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01238-x · Cited by 863 · see citing works
Monoclonal Antibodies in Cancer Therapy
Zahavi, D. J., & Weiner, L. M. (2020) · Antibodies · doi:10.3390/antib9030034 · Cited by 845 · see citing works
The changing therapeutic landscape of head and neck cancer
Cramer, J. D., Burtness, B. A., Le, Q., & Ferris, R. L. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0227-z · Cited by 794 · see citing works
Self-citation
The secret ally: immunostimulation by anticancer drugs
Galluzzi, L., Senovilla, L., Zitvogel, L., & Kroemer, G. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3626 · Cited by 670 · see citing works
Immunology and Immunotherapy of Head and Neck Cancer
Ferris, R. L. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.1509 · Cited by 668 · see citing works
Self-citation
Tumour-infiltrating B cells: immunological mechanisms, clinical impact and therapeutic opportunities
Laumont, C. M., Banville, A. C., Gilardi, M., Hollern, D. P., & Nelson, B. H. (2022) · Nature reviews. Cancer · doi:10.1038/s41568-022-00466-1 · Cited by 534 · see citing works
Immunotherapy of cancer in 2012
Kirkwood, J. M., Butterfield, L. H., Tarhini, A. A., Zarour, H. M., Kaliński, P., & Ferrone, S. (2012) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.20132 · Cited by 436 · see citing works
Self-citation
Amphiregulin Enhances Regulatory T Cell-Suppressive Function via the Epidermal Growth Factor Receptor
Zaiss, D. M. W., van Loosdregt, J., Gorlani, A., Bekker, C. P. J., Gröne, A., Sibilia, M. C., Henegouwen, P. M. P. V. B. E., Roovers, R. C., Coffer, P. J., & Sijts, A. J. A. M. (2013) · Immunity · doi:10.1016/j.immuni.2012.09.023 · Cited by 418 · see citing works
Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib
Carey, L., Berry, D. A., Cirrincione, C., Barry, W. T., Pitcher, B. N., Harris, L. N., Ollila, D. W., Krop, I. E., Henry, N. L., Weckstein, D. J., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.1268 · Cited by 421 · see citing works
2011: the immune hallmarks of cancer
Cavallo, F., Giovanni, C. D., Nanni, P., Forni, G., & Lollini, P. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-010-0968-0 · Cited by 417 · see citing works
A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer
Mellor, J. D., Brown, M. P., Irving, H. R., Zalcberg, J. R., & Dobrovic, A. (2013) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-6-1 · Cited by 417 · see citing works
Monoclonal Antibodies for Cancer Therapy
Scott, A. M., Allison, J. P., & Wolchok, J. D. (2012) · SpringerReference · doi:10.1007/springerreference_303431 · Cited by 413 · see citing works
Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
Srivastava, R. M., Lee, S. C., Filho, P. A. A., Lord, C. A., Jie, H.-B., Davidson, H. C., López‐Albaitero, A., Gibson, S. P., Gooding, W. E., Ferrone, S., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2426 · Cited by 321 · see citing works
Self-citation
The immune system and response to HER2-targeted treatment in breast cancer
Bianchini, G., & Gianni, L. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70477-7 · Cited by 282 · see citing works
CTLA-4+ Regulatory T Cells Increased in Cetuximab-Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis
Jie, H.-B., Schuler, P. J., Lee, S. C., Srivastava, R. M., Argiris, A. E., Ferrone, S., Whiteside, T. L., & Ferris, R. L. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2788 · Cited by 267 · see citing works
Self-citation
EGFR as a Target for Glioblastoma Treatment: An Unfulfilled Promise
Westphal, M., Maire, C. L., & Lamszus, K. (2017) · CNS Drugs · doi:10.1007/s40263-017-0456-6 · Cited by 223 · see citing works
A randomised, open label phase III trial with nimotuzumab, an anti-epidermal growth factor receptor monoclonal antibody in the treatment of newly diagnosed adult glioblastoma
Westphal, M., Heese, O., Steinbach, J. P., Schnell, O., Schackert, G., Mehdorn, H. M., Schulz, D., Simon, M., Schlegel, U. S., Senft, C., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2014.12.019 · Cited by 213 · see citing works
Immunomodulation by targeted anticancer agents
Petroni, G., Buqué, A., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.11.009 · Cited by 212 · see citing works
Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma
van de Donk, N. W. C. J., Moreau, P., Plesner, T., Palumbo, A. P., Gay, F., Laubach, J. P., Malavasi, F., Avet‐Loiseau, H., Mateos, M., Sonneveld, P., et al. (2015) · Blood · doi:10.1182/blood-2015-10-646810 · Cited by 204 · see citing works
HER2-targeted therapies in gastric cancer
Zhu, Y., Zhu, X., Wei, X., Tang, C., & Zhang, W. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188549 · Cited by 202 · see citing works
Emerging Targeted Therapies for HER2-Positive Breast Cancer
Mercogliano, M. F., Bruni, S., Mauro, F. L., & Schillaci, R. (2023) · Cancers · doi:10.3390/cancers15071987 · Cited by 203 · see citing works
Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients
Petričević, B., Laengle, J., Singer, J., Sachet, M., Fazekas, J., Steger, G. G., Bartsch, R., Jensen‐Jarolim, E., & Bergmann, M. M. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-307 · Cited by 196 · see citing works
T Lymphocytes Expressing a CD16 Signaling Receptor Exert Antibody-Dependent Cancer Cell Killing
Kudo, K., Imai, C., Lorenzini, P. A., Kamiya, T., Kono, K., Davidoff, A. M., Chng, W. J., & Campana, D. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1365 · Cited by 187 · see citing works
Autonomous growth and increased cytotoxicity of natural killer cells expressing membrane-bound interleukin-15
Imamura, M., Shook, D. R., Kamiya, T., Shimasaki, N., Chai, S. M. H., Coustan‐Smith, E., Imai, C., & Campana, D. (2014) · Blood · doi:10.1182/blood-2014-02-556837 · Cited by 186 · see citing works
VTX-2337 Is a Novel TLR8 Agonist That Activates NK Cells and Augments ADCC
Lu, H., Dietsch, G. N., Matthews, M.-A. H., Yang, Y., Ghanekar, S., Inokuma, M. S., Suni, M. A., Maino, V. C., Henderson, K. E., Howbert, J. J., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1625 · Cited by 180 · see citing works
Mechanisms behind the Resistance to Trastuzumab in HER2-Amplified Breast Cancer and Strategies to Overcome It
Luque-Cabal, M., García‐Teijido, P., Fernández-Pérez, Y., Sánchez‐Lorenzo, L., & Vázquez, I. P. (2016) · Clinical Medicine Insights Oncology · doi:10.4137/cmo.s34537 · Cited by 182 · see citing works
Synergistic Innate and Adaptive Immune Response to Combination Immunotherapy with Anti-Tumor Antigen Antibodies and Extended Serum Half-Life IL-2
Zhu, E. F., Gai, S. A., Opel, C. F., Kwan, B. H., Surana, R., Mihm, M. C., Kauke, M. J., Moynihan, K. D., Angelini, A., Williams, R. T., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.004 · Cited by 177 · see citing works
Monoclonal antibodies for the treatment of cancer
Shuptrine, C. W., Surana, R., & Weiner, L. M. (2012) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2011.12.009 · Cited by 172 · see citing works
Nanomedicine‐Based Immunotherapy for the Treatment of Cancer Metastasis
Zhang, P., Zhai, Y., Cai, Y., Zhao, Y., & Li, Y. (2019) · Advanced Materials · doi:10.1002/adma.201904156 · Cited by 170 · see citing works
Whole Cell Vaccines—Past Progress and Future Strategies
Keenan, B. P., & Jaffee, E. M. (2012) · Seminars in Oncology · doi:10.1053/j.seminoncol.2012.02.007 · Cited by 167 · see citing works
Self-citation
Circulating exosomes measure responses to therapy in head and neck cancer patients treated with cetuximab, ipilimumab, and IMRT
Theodoraki, M., Yerneni, S. S., Gooding, W. E., Ohr, J. P., Clump, D. A., Bauman, J. E., Ferris, R. L., & Whiteside, T. L. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1593805 · Cited by 163 · see citing works
Self-citation
PD-L1 Mediates Dysfunction in Activated PD-1+ NK Cells in Head and Neck Cancer Patients
Concha‐Benavente, F., Kansy, B., Moskovitz, J. M., Moy, J. D., Chandran, U. R., & Ferris, R. L. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0062 · Cited by 162 · see citing works
Self-citation
Evidence-Based Treatment Options in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
Argiris, A. E., Harrington, K. J., Tahara, M., Schulten, J., Chomette, P., Castro, A. F., & Licitra, L. F. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00072 · Cited by 161 · see citing works
Immunotherapy for Head and Neck Squamous Cell Carcinoma
Moskovitz, J. M., Moy, J. D., & Ferris, R. L. (2018) · Current Oncology Reports · doi:10.1007/s11912-018-0654-5 · Cited by 162 · see citing works
Self-citation
Targeting CD137 enhances the efficacy of cetuximab
Kohrt, H. E., Colevas, A. D., Houot, R., Weiskopf, K., Goldstein, M. J., Lund, P., Mueller, A., Sagiv-Barfi, I., Marabelle, A., Lira, R., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci73014 · Cited by 160 · see citing works
Retracted
Natural killer (NK): dendritic cell (DC) cross talk induced by therapeutic monoclonal antibody triggers tumor antigen-specific T cell immunity
Lee, S. C., Srivastava, R. M., López-Albaitero, A., Ferrone, S., & Ferris, R. L. (2011) · Immunologic Research · doi:10.1007/s12026-011-8231-0 · Cited by 156 · see citing works
Self-citation
Trastuzumab Increases HER2 Uptake and Cross-Presentation by Dendritic Cells
Gall, V., Philips, A. V., Qiao, N., Clise-Dwyer, K., Perakis, A. A., Zhang, M., Clifton, G. T., Sukhumalchandra, P., Ma, Q., Reddy, S. M., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2774 · Cited by 156 · see citing works
Targeting immune checkpoints in breast cancer: an update of early results
Solinas, C., Gombos, A., Latifyan, S., Piccart, M. J., Kok, M., & Buisseret, L. (2017) · ESMO Open · doi:10.1136/esmoopen-2017-000255 · Cited by 152 · see citing works
Amphiregulin Confers Regulatory T Cell Suppressive Function and Tumor Invasion via the EGFR/GSK-3β/Foxp3 Axis
Wang, S., Zhang, Y., Wang, Y., Ye, P., Li, J., Li, H., Ding, Q., & Xia, J. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.717892 · Cited by 147 · see citing works
In Vivo Applications of Single Chain Fv (Variable Domain) (scFv) Fragments
Monnier, P. P., Vigouroux, R. J., & Tassew, N. G. (2013) · Antibodies · doi:10.3390/antib2020193 · Cited by 135 · see citing works
Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)- and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC)
Cohen, R. B. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.10.002 · Cited by 135 · see citing works
Human Xeno-Autoantibodies against a Non-Human Sialic Acid Serve as Novel Serum Biomarkers and Immunotherapeutics in Cancer
Padler‐Karavani, V., Hurtado‐Ziola, N., Pu, M., Yu, H., Huang, S., Muthana, S. M., Chokhawala, H. A., Cao, H., Secrest, P., Friedmann‐Morvinski, D., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4102 · Cited by 133 · see citing works
Myeloid-Derived Suppressor Cells and anti-tumor T cells: a complex relationship
Monu, N. R., & Frey, A. B. (2012) · Immunological Investigations · doi:10.3109/08820139.2012.673191 · Cited by 130 · see citing works
Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial
Bianchini, G., Pusztai, L., Pieńkowski, T., Im, Y., Bianchi, G., Tseng, L., Liu, M.-C., Lluch, A. M., Galeota, E., Magazzù, D., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv395 · Cited by 131 · see citing works
Enhancing antibody-dependent cell-mediated cytotoxicity: a strategy for improving antibody-based immunotherapy
Zahavi, D. J., Aldeghaither, D. S., O’Connell, A., & Weiner, L. M. (2018) · Antibody Therapeutics · doi:10.1093/abt/tby002 · Cited by 128 · see citing works
Promising systemic immunotherapies in head and neck squamous cell carcinoma
Gildener‐Leapman, N., Ferris, R. L., & Bauman, J. E. (2013) · Oral Oncology · doi:10.1016/j.oraloncology.2013.09.009 · Cited by 116 · see citing works
Self-citation
Functional and Clinical Relevance of Chondroitin Sulfate Proteoglycan 4
Campoli, M. R., Ferrone, S., & Wang, X. (2010) · Advances in cancer research · doi:10.1016/b978-0-12-380890-5.00003-x · Cited by 113 · see citing works
Self-citation
Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide GP2 vaccine in breast cancer patients to prevent recurrence
Mittendorf, E. A., Ardavanis, A. S., Litton, J. K., Shumway, N. M., Hale, D. F., Murray, J. L., Perez, S. A., Ponniah, S., Baxevanis, C. N., Papamichail, M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11751 · Cited by 112 · see citing works
Triple-Negative Breast Cancer: Immune Modulation as the New Treatment Paradigm
Disis, M. L., & Stanton, S. E. (2015) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2015.35.e25 · Cited by 108 · see citing works
The role of complement in the mechanism of action of therapeutic anti-cancer mAbs
Golay, J., & Taylor, R. P. (2020) · Antibodies · doi:10.3390/antib9040058 · Cited by 104 · see citing works
Biological mechanisms of immune escape and implications for immunotherapy in head and neck squamous cell carcinoma
Moy, J. D., Moskovitz, J. M., & Ferris, R. L. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2016.12.035 · Cited by 99 · see citing works
Self-citation
Metronomic cyclophosphamide eradicates large implanted GL261 gliomas by activating antitumor Cd8 + T-cell responses and immune memory
Wu, J., & Waxman, D. J. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1005521 · Cited by 97 · see citing works
Results of a Randomized Phase IIb Trial of Nelipepimut-S + Trastuzumab versus Trastuzumab to Prevent Recurrences in Patients with High-Risk HER2 Low-Expressing Breast Cancer
Clifton, G. T., Hale, D. F., Vreeland, T. J., Hickerson, A. T., Litton, J. K., Alatrash, G., Murthy, R. K., Qiao, N., Philips, A. V., Lukas, J. J., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2741 · Cited by 95 · see citing works
TLR2 Agonist PSK Activates Human NK Cells and Enhances the Antitumor Effect of HER2-Targeted Monoclonal Antibody Therapy
Lu, H., Yang, Y., Gad, E. A., Inatsuka, C., Wenner, C. A., Disis, M. L., & Standish, L. J. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1142 · Cited by 91 · see citing works
Targeting Neuroinflammation in Brain Cancer: Uncovering Mechanisms, Pharmacological Targets, and Neuropharmaceutical Developments
Alghamri, M. S., McClellan, B. L., Hartlage, C. S., Haase, S., Faisal, S. M., Thalla, R., Dabaja, A. A., Banerjee, K., Carney, S. V., Mujeeb, A., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.680021 · Cited by 89 · see citing works
Expanded and armed natural killer cells for cancer treatment
Shimasaki, N., Coustan‐Smith, E., Kamiya, T., & Campana, D. (2016) · Cytotherapy · doi:10.1016/j.jcyt.2016.06.013 · Cited by 87 · see citing works
Phase Ib Study of Immune Biomarker Modulation with Neoadjuvant Cetuximab and TLR8 Stimulation in Head and Neck Cancer to Overcome Suppressive Myeloid Signals
Shayan, G., Kansy, B., Gibson, S. P., Srivastava, R. M., Bryan, J. K., Bauman, J. E., Ohr, J. P., Kim, S., Duvvuri, U., Clump, D. A., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0357 · Cited by 83 · see citing works
Self-citation
Antibodies in oncology
Pillay, V., Gan, H. K., & Scott, A. M. (2011) · New Biotechnology · doi:10.1016/j.nbt.2011.03.021 · Cited by 80 · see citing works
Enhanced Natural Killer Cell Immunotherapy by Rationally Assembling Fc Fragments of Antibodies onto Tumor Membranes
Ji, T., Lang, J., Ning, B., Qi, F., Wang, H., Zhang, Y., Zhao, R., Yang, X. P., Zhang, L., Li, W., et al. (2018) · Advanced Materials · doi:10.1002/adma.201804395 · Cited by 80 · see citing works
Harnessing CD16-Mediated NK Cell Functions to Enhance Therapeutic Efficacy of Tumor-Targeting mAbs
Capuano, C., Pighi, C., Battella, S., Federicis, D. D., Galandrini, R., & Palmieri, G. (2021) · Cancers · doi:10.3390/cancers13102500 · Cited by 78 · see citing works
Aberrantly glycosylated MUC1 is expressed on the surface of breast cancer cells and a target for antibody-dependent cell-mediated cytotoxicity
Lavrsen, K., Madsen, C. B., Rasch, M. G., Woetmann, A., Ødum, N., Mandel, U., Clausen, H., Pedersen, A. E., & Wandall, H. H. (2012) · Glycoconjugate Journal · doi:10.1007/s10719-012-9437-7 · Cited by 78 · see citing works
Cetuximab ± chemotherapy enhances dendritic cell‐mediated phagocytosis of colon cancer cells and ignites a highly efficient colon cancer antigen‐specific cytotoxic T‐cell response in vitro
Correale, P., Botta, C., Cusi, M. G., Vecchio, M. T. D., Santi, M. M. D., Savellini, G. G., Bestoso, E., Apollinari, S., Mannucci, S., Marra, M., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.26181 · Cited by 77 · see citing works
TLR8 stimulation enhances cetuximab-mediated natural killer cell lysis of head and neck cancer cells and dendritic cell cross-priming of EGFR-specific CD8+ T cells
Stephenson, R. M., Lim, C. M., Matthews, M., Dietsch, G. N., Hershberg, R. M., & Ferris, R. L. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1437-3 · Cited by 70 · see citing works
Self-citation
Nimotuzumab: beyond the EGFR signaling cascade inhibition
Mazorra, Z., Chao, L., Lavastida, A., Sanchez, B., Ramos, M., Iznaga, N., & Crombet, T. (2018) · Seminars in Oncology · doi:10.1053/j.seminoncol.2018.04.008 · Cited by 70 · see citing works
Radiation therapy and immunotherapy: Implications for a combined cancer treatment
Lévy, A., Chargari, C., Cheminant, M., Simon‐Tillaux, N., Bourgier, C., & Deutsch, É. (2012) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2012.09.001 · Cited by 69 · see citing works
Tumor immunotherapy: New aspects of natural killer cells
Li, Y., & Sun, R. (2018) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2018.02.02 · Cited by 68 · see citing works
Phase I Trial of Expanded, Activated Autologous NK-cell Infusions with Trastuzumab in Patients with HER2-positive Cancers
Lee, S. C., Shimasaki, N., Lim, J. S. J., Wong, A. L., Yadav, K., Yong, W. P., Tan, L. K., Koh, L. P., Poon, M. L. M., Tan, S. H., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0768 · Cited by 68 · see citing works
Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone
Persky, D. O., Dornan, D., Goldman, B. H., Braziel, R. M., Fisher, R. I., LeBlanc, M. L., Maloney, D. G., Press, O. W., Miller, T., & Rimsza, L. M. (2012) · Haematologica · doi:10.3324/haematol.2011.050419 · Cited by 68 · see citing works
HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models
Wang, D., Qian, G., Zhang, H., Magliocca, K. R., Nannapaneni, S., Amin, A. R. M. R., Rossi, M., Patel, M. R., El‐Deiry, M. W., Wadsworth, J. T., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0558 · Cited by 68 · see citing works
Anti-GD2 mAb and Vorinostat synergize in the treatment of neuroblastoma
Kroesen, M., Büll, C., Gielen, P. R., Brok, I. C., Armandari, I., Wassink, M., Looman, M. W. G., Boon, L., den Brok, M. H., Hoogerbrugge, P. M., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1164919 · Cited by 66 · see citing works
Natural killer (NK) cells and anti-tumor therapeutic mAb: unexplored interactions
Battella, S., Cox, M. C., Santoni, A., & Palmieri, G. (2015) · Journal of Leukocyte Biology · doi:10.1189/jlb.5vmr0415-141r · Cited by 66 · see citing works
Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti‐cancer antibodies: IUPHAR Review 18
Carvalho, S., Levi‐Schaffer, F., Sela, M., & Yarden, Y. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13450 · Cited by 64 · see citing works
Novel Linear Peptides with High Affinity to αvβ3 Integrin for Precise Tumor Identification
Ma, Y., Ai, G., Zhang, C., Zhao, M., Dong, X., Han, Z., Wang, Z., Zhang, M., Liu, Y., Gao, W., et al. (2017) · Theranostics · doi:10.7150/thno.18401 · Cited by 62 · see citing works
Nimotuzumab Induces NK Cell Activation, Cytotoxicity, Dendritic Cell Maturation and Expansion of EGFR-Specific T Cells in Head and Neck Cancer Patients
Mazorra, Z., Lavastida, A., Concha‐Benavente, F., Valdés, A. F.-C., Srivastava, R. M., García-Bates, T. M., Esperanza, H., González, Z., González, A., Lugiollo, M., et al. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00382 · Cited by 61 · see citing works
Self-citation
CD16+ fibroblasts foster a trastuzumab-refractory microenvironment that is reversed by VAV2 inhibition
Liu, X., Lu, Y., Huang, J., Xing, Y., Dai, H., Zhu, L., Li, S., Feng, J., Zhou, B., Li, J., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.10.015 · Cited by 59 · see citing works
The clinical implications of antitumor immunity in head and neck cancer
Allen, C. T., Judd, N. P., Bui, J. D., & Uppaluri, R. (2011) · The Laryngoscope · doi:10.1002/lary.21913 · Cited by 59 · see citing works
The addition of IMiDs for patients with daratumumab-refractory multiple myeloma can overcome refractoriness to both agents
Gavriatopoulou, M., Kastritis, E., Ntanasis‐Stathopoulos, I., Fotiou, D., Ρούσσου, Μ., Migkou, M., Ziogas, D. C., Kanellias, N., Terpos, E., & Dimopoulos, M. A. (2017) · Blood · doi:10.1182/blood-2017-10-809293 · Cited by 59 · see citing works
Integrating novel therapeutic monoclonal antibodies into the management of head and neck cancer
Bauman, J. E., & Ferris, R. L. (2013) · Cancer · doi:10.1002/cncr.28380 · Cited by 58 · see citing works
Self-citation
The Immune Response to Tumors as a Tool toward Immunotherapy
Pandolfi, F., Cianci, R., Pagliari, D., Casciano, F., Bagalá, C., Astone, A., Landolfi, R., & Barone, C. A. (2011) · Clinical and Developmental Immunology · doi:10.1155/2011/894704 · Cited by 58 · see citing works
Carbohydrate-based cancer vaccines: target cancer with sugar bullets
Liu, C., & Ye, X. (2012) · Glycoconjugate Journal · doi:10.1007/s10719-012-9399-9 · Cited by 56 · see citing works
Neuroblastoma patients with high-affinity FCGR2A, -3A and stimulatory KIR 2DS2 treated by long-term infusion of anti-GD2 antibody ch14.18/CHO show higher ADCC levels and improved event-free survival
Siebert, N., Jensen, C., Troschke‐Meurer, S., Zumpe, M., Jüttner, M., Ehlert, K., Kietz, S., Müller, I., & Lode, H. N. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1235108 · Cited by 56 · see citing works
The Current Status and Prospects of Antibody Engineering for Therapeutic Use: Focus on Glycoengineering Technology
Niwa, R., & Satoh, M. (2015) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24316 · Cited by 55 · see citing works
T lymphocytes engineered to express a CD16-chimeric antigen receptor redirect T-cell immune responses against immunoglobulin G–opsonized target cells
D’Aloia, M. M., Caratelli, S., Palumbo, C., Battella, S., Arriga, R., Lauro, D., Palmieri, G., Sconocchia, G., & Alimandi, M. (2015) · Cytotherapy · doi:10.1016/j.jcyt.2015.10.014 · Cited by 52 · see citing works
Tumor microenvironmental modification by the current target therapy for head and neck squamous cell carcinoma
Okuyama, K., Naruse, T., & Yanamoto, S. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02691-4 · Cited by 54 · see citing works
PD-1 blockade enhances elotuzumab efficacy in mouse tumor models
Bezman, N., Jhatakia, A., Kearney, A. Y., Brender, T., Maurer, M. F., Henning, K. A., Jenkins, M. R., Rogers, A. J., Neeson, P. J., Korman, A. J., et al. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017004382 · Cited by 54 · see citing works
Toward integrative cancer immunotherapy: targeting the tumor microenvironment
Emens, L. A., Silverstein, S. C., Khleif, S. N., Marincola, F. M., & Galon, J. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-70 · Cited by 54 · see citing works
Economic evaluation of therapeutic cancer vaccines and immunotherapy: A systematic review
Geynisman, D. M., Chien, C., Smieliauskas, F., Shen, C., & Shih, Y. T. (2014) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.29407 · Cited by 52 · see citing works
Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting
Bauman, J. E., Cohen, E. E. W., Ferris, R. L., Adelstein, D. J., Brizel, D. M., Ridge, J. A., O’Sullivan, B., Burtness, B. A., Butterfield, L. H., Carson, W. E., et al. (2016) · Cancer · doi:10.1002/cncr.30449 · Cited by 51 · see citing works
Self-citation
Serum biomarkers as potential predictors of antitumor activity of cetuximab-containing therapy for locally advanced head and neck cancer
Argiris, A. E., Lee, S. C., Feinstein, T. M., Thomas, S. M., Branstetter, B. F., Seethala, R. R., Wang, L., Gooding, W. E., Grandis, J. R., & Ferris, R. L. (2011) · Oral Oncology · doi:10.1016/j.oraloncology.2011.07.034 · Cited by 50 · see citing works
Self-citation
Leveraging CD16 fusion receptors to remodel the immune response for enhancing anti-tumor immunotherapy in iPSC-derived NK cells
Meng, F., Zhang, S., Xie, J., Zhou, Y., Wu, Q., Lu, B., Zhou, S., Zhao, X., & Li, Y. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01455-z · Cited by 49 · see citing works
Control of Advanced Cancer: The Road to Chronicity
Lage, A., & Crombet, T. (2011) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph8030683 · Cited by 49 · see citing works
Immune biomarkers of anti-EGFR monoclonal antibody therapy
Trivedi, S., Concha‐Benavente, F., Srivastava, R. M., Jie, H., Gibson, S. P., Schmitt, N. C., & Ferris, R. L. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu156 · Cited by 49 · see citing works
Self-citation
Advances in Doxorubicin Chemotherapy: Emerging Polymeric Nanocarriers for Drug Loading and Delivery
Bhadran, A., Polara, H., Babanyinah, G. K., Baburaj, S., & Stefan, M. C. (2025) · Cancers · doi:10.3390/cancers17142303 · Cited by 57 · see citing works
TLR3 agonists improve the immunostimulatory potential of cetuximab against EGFR+head and neck cancer cells
Lim, C. M., Stephenson, R. M., Salazar, A. Μ., & Ferris, R. L. (2013) · OncoImmunology · doi:10.4161/onci.24677 · Cited by 48 · see citing works
Self-citation
CD8+ T Cell-Independent Immune-Mediated Mechanisms of Anti-Tumor Activity
Pluhar, G. E., Pennell, C. A., & Olin, M. R. (2015) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.2015013607 · Cited by 48 · see citing works
New Strategies in Multiple Myeloma: Immunotherapy as a Novel Approach to Treat Patients with Multiple Myeloma
Neri, P. E., Bahlis, N. J., & Lonial, S. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0184 · Cited by 47 · see citing works
Natural Killer Cell-Based Immunotherapy against Glioblastoma
Morimoto, T., Nakazawa, T., Maeoka, R., Nakagawa, I., Tsujimura, T., & Matsuda, R. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032111 · Cited by 48 · see citing works

Tumor Antigen-Specific Monoclonal Antibodies and Induction of T-Cell Immunity
Trivedi, S., Jie, H.-B., & Ferris, R. L. (2014) · Seminars in Oncology · doi:10.1053/j.seminoncol.2014.08.003 · Cited by 18 · see citing works
Self-citation
Immunotherapy of Malignant Disease with Tumor Antigen–Specific Monoclonal Antibodies
Campoli, M. R., Ferris, R. L., Ferrone, S., & Wang, X. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2345 · Cited by 71 · see citing works
Self-citation
A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer
Mellor, J. D., Brown, M. P., Irving, H. R., Zalcberg, J. R., & Dobrovic, A. (2013) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-6-1 · Cited by 417 · see citing works
肿瘤抗原靶向性单克隆抗体免疫治疗：临床反应,细胞免疫和免疫逃逸
贾志宇, Chweeming, Lim, Robert, & Ferris (2012) · Journal of Modern Stomatology
Immune biomarkers of anti-EGFR monoclonal antibody therapy
Trivedi, S., Concha‐Benavente, F., Srivastava, R. M., Jie, H., Gibson, S. P., Schmitt, N. C., & Ferris, R. L. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu156 · Cited by 49 · see citing works
Self-citation

Authors: Ferris, R. L., Jaffee, E. M., & Ferrone, S.
Affiliations: Johns Hopkins University (US)
ORCID: Ferris, Robert L.
Jaffee, Elizabeth M.
Ferrone, Soldano
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2010-10-01
Volume: 28
Issue: 28
Pages: 4390-4399
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2009.27.6360
PMC: PMC2954137
OpenAlex: W2112887207
Cited by: 320
References: 122
Citations by year: 2026: 6 · 2025: 12 · 2024: 7 · 2023: 28 · 2022: 11 · 2021: 13 · 2020: 17 · 2019: 19 · 2018: 13 · 2017: 30 · 2016: 26 · 2015: 33 · 2014: 18 · 2013: 28 · 2012: 34
FWCI: 3.94
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: Amgen
Bristol-Myers Squibb
American Society of Clinical Oncology
National Cancer Institute (P50CA097190)
National Institute of Dental and Craniofacial Research (R01DE019727)
Topics: Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Monoclonal and Polyclonal Antibodies Research
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords: antibody-dependent cellular cytotoxicity, Fc gamma receptor polymorphisms, tumor immune evasion, cell-mediated immunity, rituximab, trastuzumab, cetuximab, signaling pathway inhibition
MeSH terms: Animals, Antibodies, Monoclonal, Antigens, Neoplasm, Humans, Immunity, Cellular, Immunotherapy, Neoplasms, Receptors, Fc, Signal Transduction, Drug Resistance, Neoplasm

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Self-check

Cites

Cited by

Related

Record

About these checks